1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262.
2.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. doi: 10.3322/caac.21551.
3.Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749-68. doi: 10.1001/jamaoncol. 2019.2996.
4.DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211-33. doi: 10.3322/caac.21555.
5.Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, et al. Cancer incidence in Iran in 2014: results of the Iranian National Population-based Cancer Registry. Cancer Epidemiol. 2019;61:50-8. doi.org/10.1016/j. canep.2019.05.009.
6.Shahkhodabandeh S, Piri Z, Biglo M, Asadi M, Chakhmachi DN. Breast cancer in Iran: Iranian scientists approach to breast cancer researchers in Medline database. [In Persian] Iran J Breast Dis. 2009;2(2): 49-59.
7.Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME. Epidemiology and histopathology of breast cancer in iran versus other middle eastern countries. Middle East J Cancer. 2018;9(3):243-51. doi.10.30476/MEJC.2018.42130.
8.Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717. doi: 10.1016/ S0140-6736(05)66544-0.
9.Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738-46. doi: 10.1200/JCO. 1996.14.10.2738.
10.Mazroui Y, Mathoulin-Pélissier S, Macgrogan G, Brouste V, Rondeau V. Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data. Biom J. 2013;55(6):866-84. doi: 10.1002/bimj.201200196.
11.Putter H, van der Hage J, de Bock GH, Elgalta R, van de Velde CJ. Estimation and prediction in a multi-state model for breast cancer. Biom J. 2006;48(3): 366-80. doi: 10.1002/bimj.200510218.
12.Grover G, Swain PK, Goel K, Singh V. Multistate Markov modelling for disease progression of breast cancer patients based on CA15-3 marker. Thailand Statistician. 2018;16(2):129-39.
13.Hosseni AF, Gohari MR. Application of multilevel model in determining the effective factors in the length of stay among appendectomy patients. [In Persian] Razi Journal of Medical Sciences (RJMS). 2014;20(115):70-7.
14.Raesizadeh M, Seghatoleslami M, Hoseinzade M, Saki Malehi A. Survival analysis of breast cancer patients according to intermediate and endpoint events: Applying illness-death model. [In Persian] The Iranian Journal of Epidemiology (IJE). 2018;13(4):291-8.
15.Amirkafi M. The significance and logic of multilevel models in social research. [In Persian] Iranian J of Sociology. 2007;7(4):38-71.
16.Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017;7(2):73-9. doi: 10.1016/j.prro. 2016.09.007.
17.Broët P, de la Rochefordière A, Scholl SM, Fourquet A, De Rycke Y, Pouillart P, et al. Analyzing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat. 1999;54(1):83-9. doi: 10.1023/a:1006197524405.
18.Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-430. doi: 10.1002/ sim.2712.
19.Faradmal J, Mafi M, Sadighi-Pashaki A, Karami M, Roshanaei G. Factors affecting survival in breast cancer patients referred to the darol aitam-e mahdieh center. [In Persian] J Adv Med Biomed Res. 2014; 22(93):105-15.
20. De Bock G, Putter H, Bonnema J, Van Der Hage J, Bartelink H, Van De Velde C. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat. 2009;117(2):401-8. doi: 10.1007/ s10549-008-0300-2.
21.Hajihosseini M, Faradmal J, Sadighi-Pashaki A. Survival analysis of breast cancer patients after surgery with an intermediate event: application of illness-death model. Iran J Public Health. 2015;44(12):1677.
22.Lakzaei M, Salarilak S, Khalkhali HR, Maleki D, Esnaashari O. Association between age of morbidity and prognosis of breast cancer. [In Persian] Studies in Medical Sciences. 2015;26(7):625-33.
23.Moghadami FZ, Abolghasemi J, Asgari DA, Gohari M. Survival analysis of patients with breast cancer using the Aalen's additive hazard model. [In Persian] Journal of North Khorasan University of Medical Sciences (NKUMS). 2011;3:171-80. doi: 10.29252/ jnkums.3.5.s5.171.
24.Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14(1):52-7. doi: 10.1200/JCO.1996. 14.1.52.
25.Jackson CH. Multi-state models for panel data: the msm package for R. J Stat Softw. 2011;38(8):1-29. doi: 10.18637/jss.v038.i08.
26.Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991;338(8763):327-31. doi: 10.1016/0140-6736(91)90475-5.
27.Saint-Pierre P, Combescure C, Daurès JP, Godard P. The analysis of asthma control under a Markov assumption with use of covariates. Stat Med. 2003;22(24):3755-70. doi: 10.1002/sim.1680.